Response to ‘Reply to Gohar on “Lungs, methotrexate and psoriasis”, a comment on “Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long‐term low‐dose methotrexate for psoriasis”’

Abstract

Presenting their research work at an international conference can be the highlight of an academic career for a researcher, and an invitation to attend a conference as a

Selection of a Structure-Switching Aptamer for the Specific Methotrexate Detection

“…Nowadays, low-dose MTX is usually used for treating diseases such as Psoriasis and rheumatoid arthritis, , while high-dose MTX is used for leukemias and osteosarcomas. , However, even a low dose of MTX has side effects . High-dose MTX poses some life-threatening side effects, for example, hepatotoxicity, pancreatitis, interstitial pneumonitis, and renal failure. − Moreover, the total body clearance (40–400 mL/min) of MTX is highly variable between individuals. Significant improvement of the outcome in childhood acute lymphoblastic leukaemia can be achieved through adjusting MTX dosage based on individual patient drug clearance during the 24 h infusion. − After the start of the infusion, delayed elimination-induced MTX plasma levels ≥10 μM at 24 h, ≥1 μM at 48 h, or ≥0.1 μM at 72 h mean the risk of excessive toxicity and the need for additional injections of citrovorum factor. , …”

Ultrasensitive therapeutic drug monitoring of methotrexate by a structure-switching aptamer with cascade primer exchange reaction

“…5,6 Although MTX has a wide dosage administration range, low-dose MTX has side effects, while high-dose MTX even poses life-threatening side effects. 7–10 In addition, the total body clearance (40–400 mL min −1 ) of MTX is highly variable due to the metabolism differences between individuals. Measuring MTX in patient blood samples is believed to be important for safe medication and personalized medicine.…”